Palisade Bio appoints Margery Fischbein to Board of Directors

PALISADE BIO, INC.

Margery Fischbein appointed to the Board effective May 7, 2024; increases Board to 4 directors.
Determined independent per SEC and Nasdaq rules; appointed to Audit Committee.
Received option to purchase 1,000 shares at $7.90, vesting quarterly over 3 years.
Fischbein is Managing Director at Cassel Salpeter & Co.; previously headed healthcare investment banking at Seaport Global and FBR.
Press release issued May 7, 2024 announcing the appointment.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Margery Fischbein

Director

PALI · PALISADE BIO, INC.

Effective: 2024-05-07
Filed: May 10, 2024, 7:59 PM ET

On May 7, 2024 (the “Effective Date”), the board of directors (“Board”) of Palisade Bio, Inc. (the “Company”) appointed Margery Fischbein to the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Margery Fischbein was appointed as Director at PALISADE BIO, INC..

Action: appointed
Role: Director

Exact text from the filing

On May 7, 2024 (the “Effective Date”), the board of directors (“Board”) of Palisade Bio, Inc. (the “Company”) appointed Margery Fischbein to the Board.

View on SEC.gov

PALISADE BIO, INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-018687

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.